Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Process for the production of preformed conjugates of albumin and a therapeutic agent

A technology for conjugates and albumin, which is applied in the field of preparation of preformed conjugates of albumin and therapeutic agents, and can solve problems such as the limitation of therapeutic effects

Active Publication Date: 2009-03-11
CHANGSHAN KAIJIEJIAN BIOPHARMACEUTICAL DEV (HEBEI) CO LTD
View PDF30 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, many of the proposed therapeutic molecules are either cleared or degraded from the body, or all of the above, thus limiting their therapeutic efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for the production of preformed conjugates of albumin and a therapeutic agent
  • Process for the production of preformed conjugates of albumin and a therapeutic agent
  • Process for the production of preformed conjugates of albumin and a therapeutic agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0262] 6.1 Example 1: Purification of recombinant albumin expressed by Pichia pastoris

[0263] This example illustrates the purification of recombinant albumin expressed by Pichia pastoris by different chromatographic methods. Recombinant albumin was expressed using the Pichia expression kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.

[0264] 6.1.1 DEAE Sepharose: Weak Anion Exchange Chromatography

[0265] Purification of Pichia-expressed recombinant albumin was performed on a DEAE Sepharose column equilibrated with pH 7.0, 10 mM phosphate buffer. The following increasing salt gradients (50 ml column volume, 2 ml / min flow rate) were used: 66 mM sodium phosphate over 5 column volumes; 66 mM sodium phosphate over 2 column volumes; 200 mM sodium phosphate over 0 column volumes; Regenerated in column volume of 200 mM sodium phosphate; pH 8.0, 20 mM Tris-HCl buffer and 2 M NaCl. The purified albumin fragments in Figure 1 were eluted in fractions f...

Embodiment 2

[0272] 6.2 Example 2: Purification of recombinant albumin after mercaptoalbumin enrichment

[0273] This example illustrates the purification of Pichia pastoris expressed and mercaptoalbumin-enriched recombinant albumin using phenyl sepharose hydrophobic interaction chromatography. Recombinant albumin (0.2% final concentration) was treated with 74 mM thioglycolic acid in 250 mM Tris-acetic acid buffer for 20 hours at 4°C. Purified with pH 7.0, 20 mM sodium phosphate, 5 mM sodium caprylate and 750 mM (NH 4 ) 2 SO 4 Performed on a phenyl sepharose column equilibrated in medium. A decreasing salt gradient (5 ml column volume, 5 ml / min flow rate) was used as follows: 20 mM sodium phosphate, 5 mM sodium caprylate over 2 column volumes; washing with water over 1 column volume; 20% over 1 column volume ethanol; and more than 1 column volume of water. In Figure 5, the purified albumin fraction was in the range of 750 to 0 M (NH 4 ) 2 SO 4 Elution in a decreasing gradient. F2 ...

Embodiment 3

[0274] 6.3 Example 3: Purification of recombinant albumin after deglycosylation

[0275] This example illustrates the deglycosylation of human serum albumin by affinity chromatography using amino-phenylboronic acid and concanavalin A as ligands. Chromatography was performed in an AKTA purification unit (Amersham Biosciences, Uppsala, Sweden).

[0276] 6.3.1 Amino-phenylboronic acid chromatography on agarose

[0277] Amino-phenylboronic acid resin including agarose (Sigma, St. Louis, MO) was used pH 8.5, 4 column volumes of 0.25M ammonium acetate, 0.05MgCl 2 (0.5ml / min flow rate) rinse and equilibrate. A 25% solution of human serum albumin (Cortex Biochem, San Leandro, CA) was diluted 1:2 in equilibration buffer and loaded onto the column. The flow through (F3) was collected and the column was washed with 4 column volumes of equilibration buffer. Elution was performed with 3 column volumes of pH 8.5, 0.1M Tris and 0.2M sorbitol and collected in F2. F3 and F2 were concentra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides processes for the production of preformed albumin conjugates. In particular, the invention provides processes for the in-vitro conjugation of a therapeutic compound to recombinant albumin, wherein a therapeutic compound comprising a reactive group is contacted to recombinant albumin in solution to form a conjugate. The processes provide for conjugation to albumin species of increasing homogeneity . The resulting conjugate is purified by chromatography, in particular hydrophobic interaction chromatography comprising phenyl sepharose and butyl sepharose chromatography.

Description

[0001] This application claims priority to US Provisional Application No. 60 / 753,680, filed on December 22, 2005, the contents of which are hereby incorporated by reference in their entirety. 1. Technical field [0002] The present invention provides a method for preparing an albumin preform conjugate. The present invention specifically provides a method for in vitro coupling of a therapeutic compound and recombinant albumin, wherein the therapeutic compound comprising a reactive group is contacted with the recombinant albumin in solution to form a conjugate. 2. Background technology [0003] To be usable in humans, therapeutic molecules must meet strict criteria. In addition to being safe and effective, they must be available in sufficient quantities for a sufficient period of time to be effective in the human body. Unfortunately, many of the proposed therapeutic molecules are either cleared or degraded from the human body, or all of the above, and thus have limited therap...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/76C07K1/10C07K1/20C07K1/36C07K14/605C07K14/765C07K19/00C12P21/02A61K47/42A61K38/26A61K47/48
CPCA61K47/48284C07K14/76C07K14/57563C07K14/57545C07K14/605C07K14/58A61K38/00C07K14/60C07K14/575C07K1/20C07K14/765A61K47/643Y02A50/30
Inventor 奥马尔·库雷希
Owner CHANGSHAN KAIJIEJIAN BIOPHARMACEUTICAL DEV (HEBEI) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com